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A complete list of amino acid abbreviations can be seen in appendix 1. 
5-HT  5-Hydroxytryptamine (serotonin) 
7TM  Seven transmembrane (receptor) 
A  Adrenaline (British Approved Name), epinephrine (International 
Nonproprietary Name) 
Cys23Ser  A single nucleotide polymorphism converting cysteine in position 23 to 
serine 
cAMP  Cyclic adenosine monophosphate 
CBS  Center for Biological Sequence Analysis 
CNS  Central nervous system 
COS-7 CV-1 origin with SV40, cell line derived from African green monkey 
kidney 
DAG  Diacyl glycerol 
ECL  Extracellular loop 
EMA  European Medicines Agency 
ER  Endoplasmic reticulum 
ERGIC ER-Golgi intermediate compartment 
FDA  Food and Drug Administration (USA) 
FSH  Follicle-stimulating hormone 
GDP  Guanosine diphosphate 
GPCR  G-protein coupled receptor 
GTP  Guanosine-5'-triphosphate 
HAsp  Influenza A hemagglutinin signal peptide  
HEK293 Human embryonic kidney 293 (cell line) 
HMM  Hidden Markov model (a statistical probability model) 
IP3  Inositol trisphosphate 
IUPHAR International Union of Basic and Clinical Pharmacology 
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Ki Equilibrium dissociation constant of a ligand determined in inhibition 
studies 
LH  Luteinizing hormone 
NA  Noradrenaline (British Approved Name), norepinephrine (International 
Nonproprietary Name)  
PCR  Polymerase chain reaction 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PKC  Protein kinase C 
pKi The negative logarithm to base 10 of the equilibrium dissociation 
constant Ki  
PLC  Phospholipase C 
PNS  Peripheral nervous system 
SNP  Single nucleotide polymorphism 
SNRI  Serotonin and norepinephrine reuptake inhibitor 
SRP  Signal recognition particle 
SSRI  Selective serotonin re-uptake inhibitor 
TGN  Trans-Golgi network 
TM  Transmembrane (helix) 
TMHMM Prediction of transmembrane helices in proteins (software) 
TSH  Thyroid-stimulating hormone 
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Abstract 
Background: G-protein coupled receptors (GPCRs) have seven transmembrane 
helices and are situated in the cell membrane, where they transduce signals from 
specific ligands to the interior of the cell. The first step in the path toward a 
functional GPCR is the synthesis and incorporation of the evolving receptor into the 
endoplasmic reticulum (ER) membrane. This process is named cotranslational 
translocation and is directed by a hydrophobic signal sequence located either in the 
N-terminus or in the first transmembrane segment (TM1). When the signal sequence 
is located in the N-terminus, it is cleaved off after translocation and is called a signal 
peptide (SP). When the signal sequence is part of the TM1 it is called a signal anchor. 
Monoamine GPCRs have in general short N-termini and are expected to use their 
TM1 as a signal anchor. Two monoamine GPCRs are nevertheless predicted by a SP 
prediction software to have signal peptides: The 5-HT2C receptor and the Į2C-
adrenoceptor. For the 5-HT2C receptor the consequence of having the predicted SP is 
that a single nucleotide polymorphism (SNP) will not be present in the mature 
receptor in the cell membrane. This SNP (Cys23Ser) has in several studies been 
associated with numerous clinical conditions and outcomes of pharmacotherapy. The 
Į2C-adrenoceptor is poorly expressed at the cell surface and has a large intracellular 
pool of receptors. It has been shown previously for other receptors that by adding a 
cleavable signal peptide sequence immediately upstream to the endogenous N-
terminus, the expression levels of ȕ2- and Į1D-adrenoceptor are greatly enhanced. 
Consequently, it is seemingly odd that the poorly expressed Į2C-adrenoceptor is 
predicted to contain a SP.   
Objective: The primary aim was to determine whether the monoamine GPCRs 5-
HT2C and Į2C have cleavable signal peptides as predicted. A secondary aim was to 
determine what relevance the N-termini of the 5-HT2C and Į2C receptors have for 
expression levels of the receptors. 
Materials and methods: Methods included engineering receptor constructs and 
chimeras by PCR and transiently transfecting COS-7 and HEK293 cells. Receptor 
constructs containing FLAG epitope were investigated with the primary antibodies 
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M1 and M2 in epifluorescence and confocal microscopy. Expression levels of wild 
type and rebuilt receptor constructs were determined by radioligand binding 
performed on membrane preparations. For Į2C-adrenoceptors radioligand binding was 
also performed on whole cells, matching the membranes, to exclude binding to an 
intracellular pool of receptors. 
Results and Conclusions: The 5-HT2C receptor has a 32 amino acid long cleavable 
signal peptide, as predicted by its amino acid sequence. When the signal peptide is 
made non-cleavable by changing one amino acid, the expression level of the receptor 
is reduced by 70%. We therefore conclude that a 32 amino acid long cleavable signal 
peptide is participating in the integration of the 5-HT2C receptor into the ER 
membrane. Consequently, the mature receptor does not contain the aforementioned 
Cys23Ser SNP. The Į2C-adrenoceptor does not possess a 22 amino acid long 
cleavable signal peptide. Among the Į2C-adrenoceptor constructs, expression was 
highest for the wild type receptor where the endogenous N-terminus was retained. 
Furthermore, all attempts at increasing the expression level of the Į2C-adrenoceptor 
by adding a known SP or by truncating the N-tail, failed. We conclude that the N-
terminus is not a major contributor to the low expression level of the Į2C-
adrenoceptor.  
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1. INTRODUCTION 
1.1 G-PROTEIN COUPLED RECEPTORS 
A primary component of cellular life is the ability to communicate. For non-adjacent 
cell-to-cell communication this always means sending and receiving messages as 
chemical signals. As the majority of chemical signaling involves hydrophilic ligands 
unable to penetrate the lipid bilayer of the target cell, there is a need for cell-surface 
proteins to transduce the signal to the interior of the cell. The proteins that sense the 
chemical signals are termed receptors and can be divided into the four superfamilies, 
shown in figure 1: Ligand gated ion channels, G-protein coupled receptors, Kinase 
linked receptors and Nuclear receptors. All these receptors except the nuclear 
receptors are localized to the cell surface membrane. 
Figure 1. Overview of the four receptor superfamilies. 1: Ion channels, 2: G-protein 
coupled receptors, 3: Kinase linked receptors, 4: Nuclear receptors. The figure illustrates 
how the receptors are situated in relation to the cell membrane, and how stimulation with an 
agonist leads to altered cell function. Taken from [1]. 
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The largest family of cell-surface receptors is the G-protein-coupled receptors 
(GPCRs). The GPCRs play an essential role in modulating various physiological 
functions, and at least a third of all currently prescribed pharmaceutical drugs are 
acting on GPCRs [2, 3], with annual revenues in excess of $40 billion [3], illustrating 
their importance as drug targets. The common structural features of GPCRs are seven 
hydrophobic transmembrane helices (TM1-TM7) spanning the cell membrane. The 
N-terminus is localized extracellular and the C-terminus is localized intracellular. 
Ligands interact with GPCRs at binding sites between the transmembrane helices 
and/or at the extracellular surfaces. Intracellular parts of the receptor interact with G-
proteins, which is short for heterotrimeric GTP-binding proteins. The general 
structure of a GPCR interacting with a G-protein can be seen in figure 2.  
Figure 2. A three-dimensional structure of a G-protein coupled receptor embedded in 
a cell membrane, including the intracellular G-protein subunits. A GPCR (magenta) in 
the plasma membrane with a ligand (yellow), and intracellularly the three G-protein subunits 
(gold, dark green and blue), GTP (bright green) and GDP (red). Taken from [4]. 
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There are 1352 genes coding for physiological receptors in the genome, and of these 
901 genes are coding for GPCRs with seven transmembrane helices [5]. The 
uncertainty whether G-proteins are involved in signal transduction for all GPCRs 
supports the notion that a more correct term would be 7TM receptors, and the terms 
GPCRs and 7TM receptors are used interchangeably in the literature. The G-protein-
coupled receptors in the human genome form five main families [6]. Since only three 
of these families/classes are targets for clinically used drugs, the International Union 
of Basic and Clinical Pharmacologys Committee on Receptor Nomenclature and 
Drug Classification (NC-IUPHAR), divides the druggable GPCRs into the three 
classes: A (Rhodopsin), B (Secretin) and C (Glutamate). Excluding the large group of 
approximately 400 olfactory odorant receptors which are members of the Rhodopsin 
family, IUPHAR and the British Pharmacological Society (BPS) in its database 
updated in June 2014 officially recognizes 394 7TM receptors of which 388 are 
designated GPCRs. 129 of the 388 GPCRs are orphan receptors with no endogenous 
ligand conclusively determined [7]. A condensed version of the IUPHAR database 
current to late 2013 is published in the “The concise guide to pharmacology 2013/14: 
G protein-coupled receptors”. As of late 2013 the rhodopsin family (Class A) 
contained 197 receptors with known ligands and 89 orphans, Class B had 15 
receptors with known ligands and no orphans and Class C had 12 receptors with 
known ligands and 8 orphans [8]. The IUPHAR classification system divides the 
receptors in families and subtypes based on pharmacology, signal transduction and 
structure [7]. 
1.1.1 G-proteins 
When a ligand binds to a GPCR, the receptor undergoes a conformational change that 
affects its intracellular coupling to a heterotrimeric GTP-binding protein, i.e. a G-
protein. The G-protein is attached to the cell membrane facing the cytosol and 
consists of the three subunits Į, ȕ and Ȗ, which make up the two functional entities Į
and ȕȖ. The conformational change of the receptor induces the Į-subunit to exchange 
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GDP for GTP, with the receptor acting as a direct guanine nucleotide exchange 
factor. In the classical model this leads to dissociation of the Į-GTP complex and ȕȖ
complex. The Į-GTP complex will then activate an intracellular second messenger 
system which will relay the message as intended. When the Į-GTP complex is 
binding to the intracellular enzymes that produce the second messengers, the GTP is 
prone for GTPase activity. The hydrolysis of GTP to GDP returns the Į-subunit to the 
inactive state and reformation of the ĮȕȖ-complex [9]. The G-proteins are defined by 
the properties of the Į-subunit, since principal transduction historically is defined by 
the established GĮ-signaling [10]. 
There are several isoforms of Į and ȕȖ subunits, and the 16 mammalian Į-subunits 
can be divided into four families: GĮs, GĮi/0, GĮq/11 and GĮ12/13. If the reader wish to 
see an overview of the different G-proteins, IUPHAR/BPS have made an introduction 
to GPCRs on the www.GuideToPharmacology.org portal [10]. The two members of 
the stimulatory GĮs proteins couples to adenylate cyclase, causing an increase in 
intracellular cAMP levels. The eight members of the GĮi/0 family are often inhibitory 
in character, for example the three Gi-proteins harboring Įi-1, Įi-2 and Įi-3 inhibit 
adenylate cyclase and cause a decrease in cAMP levels, thereby kind of having the 
opposite effect compared to GĮs-coupling. The four members of the GĮq/11 family 
activates phospholipase Cȕ  (PLCȕ), which in turn results in intramembrane 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of Ca2+ from 
intracellular stores by binding to the IP3 receptor, which is a Ca2+ channel, on the 
endoplasmic reticulum. DAG increases the activity of the enzyme protein kinase C 
(PKC), which controls the function of other proteins by phosphorylation. The two 
members of the GĮ12/13 family regulate the Ras subfamily of Rho proteins. The Rho 
proteins are small monomeric GTP-binding proteins involved in regulating cell 
morphology like organelle development, cytoskeletal dynamics and cell movement 
[9]. The GĮs, GĮi/0 and GĮq/11 families activate the classic GPCR signaling pathways 
within pharmacology. Some typical second messenger cell responses following 
agonist binding and receptor activation can be seen in figure 3. 
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Figure 3. An overview of classical G-protein signaling and second messenger system 
for GĮq, GĮs and GĮi. Taken from [9].
1.1.2 The Rhodopsin family of GPCRs (Class A) 
The Rhodopsin family, i.e. Class A, is by far the largest family of GPCRs, 
comprising more than 90% of the GPCRs, and lends its name from the rhodopsin 
receptor. Rhodopsin, which is localized to the retina in the eye, is a model system for 
membrane proteins and has been investigated regarding the molecular mechanism for 
vision since the early 1980s. In 2000 rhodopsin was the first GPCR to have its crystal 
structure determined, when Palcewski et al. published the bovine rhodopsin structure 
[11]. Rhodopsin is activated by photons, which transiently isomerize a molecule of 
retinal bound within the receptor. Olfactory GPCRs are chemosensory receptors that 
are activated by exogenous ligands, such as odors. These receptors are very poorly 
expressed at the cell surface when investigated in cell cultures, which makes 
characterization of them in traditional pharmacological assays either very difficult or 
almost impossible [12]. Consequently not much is known about their ligands, and 
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most of the olfactory receptors are therefore orphan receptors with no known ligands. 
The GPCRs in the body that have endogenous ligands are termed endo-GPCRs [6], 
and it is among these receptors we find the drug targets so fundamental to human 
pharmacology and drug therapy [7]. These GPCRs are defined by their endogenous 
ligands, represented by proteins, peptides, lipids, amino acids, ions, and monoamines 
derived from amino acids. The Rhodopsin family can be further subdivided into three 
groups usually termed “1A”, “1B” and “1C” [13]. In group 1A the receptors have 
small endogenous ligands that bind in a cavity between the transmembrane regions of 
the receptor. This includes rhodopsin itself as well as the GPCRs activated by 
monoamines like adrenaline and serotonin, usually designated monoamine receptors. 
One such monoamine receptor, the ȕ2-adrenoceptor, is the focus of a sustained effort 
to elucidate the specific structure, binding and G-protein interaction of druggable 
GPCRs. In 2007 the crystal structure of the ȕ2-adrenoceptor in the presence of a 
partial inverse agonist was published, obtained through two different methodological 
approaches; the receptor fused to T4 lysozyme [3] or stabilized with the monoclonal 
antibody Mab5 [14]. Subsequently, in 2013, the adrenaline-activated structure of the 
ȕ2-adrenoceptor was published [15], and a general method of using covalent agonists 
derived from the endogenous monoamine ligands for crystallization of agonist-
activated GPCRs was established in 2014 [16]. These recent achievements are likely 
to accelerate our knowledge of the structure, binding of ligands and function of the 
individual GPCRs. Although crystal structures of GPCRs are very important for 
characterizing the binding pocket and conformational changes, the method is not 
suited to characterize the extracellular N-terminal tail [14]. In group 1B the ligands 
are peptides and the binding site is extending to the extracellular loops. The 1C group 
contains GPCRs whose ligands are glycoprotein hormones like thyroid stimulating 
hormone (TSH), luteinizing hormone (LH) and follicle-stimulating hormone (FSH). 
These receptors have in common a large extracellular N-terminal tail that is involved 
in the binding of the hormone. The characteristics of these three groups of Rhodopsin 
family receptors are shown in figure 4 [9]. 
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Figure 4. General structure and binding sites for rhodopsin-like family A GPCRs.
Binding site is indicated in orange. A: Endogenous small-molecule ligands e.g. 
monoamines. B: Peptide ligands. C: Glycoprotein ligands. Taken from [9].  
1.1.3 The serotonin 5-HT2C receptor 
5-hydroxytryptamine (5-HT) is the chemical name for the neurotransmitter and local 
hormone serotonin. Serotonin is endogenously produced by a two-step conversion of 
the amino acid tryptophan to serotonin. Its degradation and excretion is mainly 
through oxidative deamination catalyzed by monoamine oxidase. The presence of the 
end-product 5-hydroxyindoleacetic acid in urine is an indicator for endogenous 5-HT 
production. Most of the serotonin is located in the enterochromaffin cells in the wall 
of the intestine, but it is also present in high concentrations in blood platelets and in 
the CNS. Serotonin, acting via membrane receptors, is a transmitter substance in the 
central nervous system (CNS), in the peripheral, including enteric, nervous system 
(PNS) and in the vasculature [17]. In humans serotonin is identified as the 
endogenous ligand for at least 12 different GPCR subtypes, as well as for a ligand 
gated ion channel classified as 5-HT3. The human serotonin GPCRs include five 5-
HT1 receptors, three 5-HT2 receptors and in addition the 5-HT4-7 receptors [8, 17] 
The 5-HT2 family consists of the 5-HT2A, 5-HT2B and 5-HT2C receptors, which 
mediate their effects mainly through coupling to the Gq/11 proteins [8]. The three 
receptors have a close sequence homology and it is a challenge to develop 
functionally selective agonists [18]. This is of great importance as activation of 5-
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HT2A is associated with hallucinogenic activity and 5-HT2B with cardiac valvulopathy 
[19]. 5-HT2C was originally known as 5-HT1C, but was later renamed 5-HT2C. The 
receptor was initially designated the “choroid plexus” receptor, but after more 
sensitive methods were developed, like in situ hybridization, it became clear that the 
distribution of the 5-HT2C receptor was wide-spread in the brain [17]. Because the 5-
HT2C receptor undergoes extensive mRNA-editing in addition to being spliced, it is 
possible that 32 different mRNAs and 24 different proteins could exist [17]. When 
the unedited receptor was compared to two extensively edited forms in a stable cell 
line, it appeared that the unedited form coupled to both Gq/11- and G13-proteins, while 
the edited forms only coupled to Gq/11-proteins [20]. mRNA editing breaks with the 
theory that “one gene encodes one protein”, and opens up the possibility for major 
differences between in vivo and in vitro pharmacology for important drug targets 
[21]. 
The Cys23Ser single nucleotide polymorphism in 5-HT2C. There is a wide-
spread single nucleotide polymorphism (SNP) termed Cys23Ser (rs6318) for the 5-
HT2C receptor, with 13% of the Caucasian population having a serine instead of a 
cysteine at position 23. This polymorphism is situated in the about 57 amino acids 
long extracellular N-terminus, and has in association studies been predicted to be 
linked to numerous psychiatric disorders and to varying outcomes from various drug 
treatments [22, 23]. The N-terminus also contains a glycosylation site at asparagine 
N39. Also the rat 5-HT2C receptor has the N39 glycosylation site, and it has been 
shown that this receptor is glycosylated [24]. The pharmacological properties of the 
SNP were extensively investigated by Fentress and colleagues in 2005 [25]. They 
failed to find any pharmacological consequences for this mutation, and concluded 
therefore that positive associations between the polymorphism and disease states may 
be due to some other factor. In addition, we have shown [26] that the SNP probably is 
not part of the mature receptor since it is cleaved off as part of the signal peptide of 
the receptor (see figure 5). Nevertheless genetic association studies continue, still in 
2014, to link this SNP with diverse conditions as premature ejaculation [27] and 
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cocaine cue reactivity [28]. The amino acid sequence and topology of 5-HT2C is 
depicted in figure 5, with the cysteine at the SNP site denoted with a red letter and 
star above it, and the cleavage site of the signal peptide with an arrow. 
Figure 5. The amino acid sequence and topology of the human 5-HT2C receptor. The 
alignments of transmembrane segments are as predicted by the CBS TMHMM Server 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/), when analyzed without the predicted signal 
peptide. The predicted cleavage site of the signal peptide is noted with blue arrow. The 
position of cysteine (C) at the single nucleotide polymorphism site Cys23Ser (rs6318) is 
noted with a red letter and a star above it. The N-linked glycosylation site N39 in the N-
terminus is noted with a green rectangle underneath.
5-HT2C as a drug target. Lorcaserin is a 5-HT2C selective agonist, with the brand 
name Belviq, approved by the Food and Drug Administration (FDA) in USA as an 
anti-obesity drug to be used in tandem with diet and exercise. The pharmaceutical 
company withdrew its application to the European Medicines Agency in 2013 
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because of the agency’s concerns over lack of effect and possible adverse effects. The 
adverse effects of concern were development of tumors in laboratory tests, the risk of 
valvulopathy and psychiatric disorders like depression [29]. From animal studies it is 
shown that mice lacking the 5-HT2C gene is severely obese and food intake regulation 
defective [30]. The receptor is attracting interest as a target for an agonist to prevent 
weight gain induced by antipsychotics [17], especially since antipsychotic drugs that 
provoke weight gain seem to be inverse agonists at the 5-HT2C receptor [31]. 5-HT2C
agonists are in addition attracting interest as potential treatment for substance abuse 
[19]. 
There is also an interest in antagonists selective for 5-HT2C. Agomelatine is an anti-
depressive drug with a unique mechanism of action, acting as agonist on 
melatonergic receptors MT1 and MT2 and as an antagonist on 5-HT2C [32]. Its 
efficacy and tolerability when compared to established antidepressants within the 
SSRI and SNRI groups, has been investigated in a Cochrane Review where the 
authors concluded the current data was too poor to draw a conclusion [33]. However, 
the slow pace in the development of new drugs acting at the 5-HT2C receptor 
highlights the need for further studies on the molecular function and physiological 
importance of this receptor. 
1.1.4 The Į2C-adrenoceptor 
The catecholamines noradrenaline (NA) and adrenaline (A) are the endogenous 
ligands for the adrenoceptors, which are divided into the three groups Į1, Į2 and ȕ, 
including in total nine subtype receptors: Į1A, Į1B, Į1D, Į2A, Į2B, Į2C, ȕ1, ȕ2, and ȕ3
[8].The human Į2-adrenoceptor subtypes Į2A, Į2B and Į2C show highly conserved 
amino acid sequences, especially in the seven transmembrane helices. The amino acid 
sequence and topology of the Į2C-adrenoceptor are shown in figure 6, with those 
amino acids that are identical in the Į2A-adrenoceptor shaded for comparison. The Į2C
N-tail sequence has not been aligned with that of Į2A since they are too different.  
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Figure 6. The Į2C-adrenoceptor, in comparison with the Į2A-adrenoceptor. Those 
amino acids that are identical in the Į2A-adrenoceptor are shaded. No alignments were 
performed before the dashed (red) line in the N-tail and between the dashed lines (red) in 
the third intracellular loop, due to the large differences in those regions. The predicted 
cleavage sites when the N-terminus is analyzed in SignalP 3.0 are noted with (blue) arrows 
and which prediction method used to obtain the result (HMM = Hidden Markov model, NN = 
neural networks). The N-linked glycosylation sites N19 and N33 in the N-terminus are noted 
with a green rectangle underneath. Modified from figure 1 in paper III [34]. 
Intriguingly the Į2C N-tail is not only unusual compared to the Į2A N-tail, but also 
when compared to other monoamine GPCRs. The Į2C N-terminus is 
uncharacteristically long with about 49 amino acids, including a hydrophobic stretch 
of 11 amino acids. There are two N-linked glycosylation sites at asparagines N19 and 
N33 in the N-terminus, that both have been verified experimentally [35]. It has also 
been shown that the receptor expressed at the cell surface is glycosylated at both 
these sites [36, 37]. In the present study we have verified by our methods that the N19 
glycosylation site is not cleaved as part of a signal peptide. Unlike Į2A and Į2B, the 
25
Į2C-adrenoceptor is poorly expressed at the cell surface and has a prominent 
intracellular pool of receptors [38]. An exception to the poor expression of the 
receptor at the cell membrane is in neuroendocrine cell lines were the receptor is 
efficiently expressed, although still with a significant intracellular pool, suggesting 
cell line specific properties concerning trafficking from intracellular compartments to 
the plasma membrane [39]. There is some controversy as to the role of the N-
terminus concerning the poor expression of the receptor [38]. One opinion on the 
matter is that the 11 amino acid hydrophobic stretch in the N-terminus function as an 
endoplasmic reticulum (ER) retention signal involved in inhibiting intracellular 
trafficking of the receptor, and thereby inhibiting the export of the Į2C-adrenoceptor 
to the plasma membrane [35]. Another opinion advocates that there is a retention 
signal in the C-terminal tail of the Į2C-adrenoceptor, and that this C-terminal retention 
signal may explain much of the low expression of the receptor at the cell surface [40]. 
All the Į2-adrenoceptors couple to G-proteins of the GĮi-family, and thus have 
similar signaling properties [7, 8]. Originally there was the perception that Į2-
adrenoceptors were only expressed at presynaptic sites, being responsible for 
inhibiting NA-release from adrenergic nerves. However, in addition to such 
presynaptic activity of Į2-adrenoceptors [41], the current knowledge implies that the 
majority of Į2-adrenoceptors are in fact localized post-synaptically [42]. The 
influence on physiological functions that the Į2-adrenoceptors are most relevant for, 
involve Į2-mediated effects in the central nervous system and the cardiovascular 
system [43]. In addition, the Į2-agonist brimonidine is lowering intraocular pressure, 
and is in clinical use in glaucoma.   
The Į2C-adrenoceptor has primarily been detected in the central nervous system [44]. 
Genetically modified mice strains with varying degrees of receptor deletion, have 
revealed the role of the Į2C-adrenoceptor as a presynaptic receptor in regulating 
noradrenaline release [45]. However, it is the Į2A-subtype that is predominant in 
controlling the release of noradrenaline from sympathetic nerves, while the more 
evasive Į2C controls release of adrenaline from the adrenal gland [41]. Knock-out 
mice lacking Į2C receptors exhibit more than two-fold augmented circulating and 
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urine levels of adrenaline [45]. By analyzing the mice phenotypes it becomes clear 
that most of the recognized Į2-mediated pharmacological effects are due to activation 
of the Į2A-subtype. This includes the antinociceptive, sedative, hypotensive, 
hypothermic and behavioral effects of Į2-agonists, as well as a possible positive 
effect on cognitive functions. The Į2C-subtype has been shown to be involved in 
modulation of dopaminergic neurotransmission and different behavioral responses, as 
well as in induction of hypothermia [45]. 
The Į2C-adrenoceptor as a drug target. Several physiological effects mediated 
by Į2-adrenoceptors seem to involve more than one subtype, with more than one 
receptor having complementary effects like Į2A and Į2C in controlling chatecolamine 
release presynaptically [46]. This opens the possibility that an Į2C-selective agonist 
might be useful, resulting in antinociceptive effect without Į2A-mediated hypotensive 
and sedative effects. Another strategy is combining an Į2C-antagonist, thereby 
blocking the Į2C-mediated presynaptic inhibition of noradrenaline and dopamine 
release, with a drug having monoamine reuptake blocking activity. This could 
speculatively be useful in treating depression, anxiety and Parkinson’s disease [47]. 
Recently, an Į2C-agonist has been investigated as nasal decongestant in animal 
models with the aim of developing a decongestant without cardiovascular actions 
[48]. 
There is a possibility that the Į2C-adrenoceptor is involved in the pathology of 
Raynaud Phenomenon, and therefore could be a drug target for treatment of this 
affliction with an Į2C-antagonist [49]. This disease is recognized by enhanced 
vasoconstriction induced by cold, emotional stress or exposure to vibrations. It seems 
like Į2C specifically modulates vascular tone at lower temperature, while being 
inactive at 37°C. This could be explained by an increased expression or effectiveness 
of Į2C-adrenoceptors at lower temperatures [40, 49]. 
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1.2 MEMBRANE LOCALIZATION OF NEWLY 
SYNTHESIZED GPCRs: FROM GENETIC CODE TO 
MATURE PROTEIN 
1.2.1 The protein secretory pathway 
The journey for a GPCR from genetic code to a functional receptor in the cell 
membrane follows the secretory pathway for proteins. To gain access to the secretory 
pathway the protein has to have a specific targeting signal that directs the 
translationally evolving protein to the endoplasmic reticulum (ER) membrane. The 
cotranslational translocation of a secretory protein is depicted in figure 7.  
Fig 7. An overview of how the newly synthesized signal sequence of a secretory 
protein (red color) interacts with the signal recognition particle (blue) and the Sec61 
complex (orange) at the endoplasmic reticulum membrane. While secretory proteins 
are completely translocated into the lumen of the ER, membrane-embedded proteins like 
GPCRs are incorporated in to the ER membrane. Figure taken from [50]. 
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Initially the signal sequence is recognized by the signal recognition particle (SRP), 
and the complex of ribosome-nascent chain-SRP interacts with the SRP receptor 
situated at the ER membrane. The SRP dissociates, and a simultaneous protein 
translation and translocation across the ER membrane ensues, controlled by the Sec61 
complex [50]. The Sec61 complex is the core unit of the translocation channel [51], 
which often is termed the translocon. If the protein is a membrane-bound receptor, it 
stays embedded in the plasma membrane by means of one or several hydrophobic 
transmembrane helices. If the protein is secreted, it passes into the ER lumen as 
depicted in figure 7 and is released extracellulary.  
1.2.2 Membrane localization directed by signal peptide or reverse 
signal anchor 
Secretory proteins all have signal peptides and are completely translocated into the 
lumen of the ER. On the other hand, GPCRs are integrated into the ER membrane 
with the appearance of a familiar seven transmembrane topology. The signal 
sequence within the GPCR family can either be a cleavable signal peptide situated in 
the N-terminus or a reverse signal anchor consisting of the first transmembrane helix 
as depicted in figure 8. When the targeting function of the signal peptide has been 
carried out, it is cleaved off by a class of enzymes known as signal peptidases [52]. 
So, the signal peptide is not present in the mature protein. It is estimated that 90-95% 
of the GPCRs do not have a signal peptide [51], but use their first transmembrane 
segment as a reverse signal anchor. As a general rule these GPCRs have short N-
terminal tails [53]. Since a general feature of the monoamine GPCRs are short N-
termini [9], they are expected to use their first transmembrane segment as a signal 
anchor.  
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Figure 8. Signal peptide function (A) and reverse signal anchor function (B) of a 
GPCR. The translocon is the channel regulating transport of proteins across and into the 
membrane, and consists of large protein complexes with Sec61 as the core unit. The red 
line with the “N” denotes the N-terminal of the receptor. SRP: Signal recognition particle. Ri: 
Ribosome. ER: Endoplasmic reticulum. Taken from [51].  
The translation and translocation process of the GPCRs, termed cotranslational 
translocation, is essentially the same whether the receptor possesses a signal peptide 
or use the first transmembrane segment as a reverse signal anchor. However, a signal 
peptide has its N-terminus embedded in the membrane, like a transmembrane 
segment, with its C-terminus in the ER lumen (see panel A in figure 8). After 
enzymatic cleavage of the signal peptide the mature receptor’s N-terminus is in the 
ER lumen. For a receptor having a first transmembrane signal anchor, the signal 
anchor is oriented towards the lumen with the N-terminus in the ER lumen. Thus, the 
main difference being a posttranslational translocation of the already synthesized N-
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terminus in the case when the first transmembrane segment functions as a reverse 
signal anchor, as depicted in panel B in figure 8. In both cases the GPCR ultimately 
gets located in the plasma membrane with an extracellular N-terminus. The core unit 
of the translocation channel, called translocon in figure 8, is the transmembrane 
protein complex Sec61 [51]. The Sec61 complex’s largest subunit is the Į-subunit, 
which has ten transmembrane segments [50]. In mammals the other two subunits are 
termed ȕ and Ȗ, and both have a single transmembrane segment. Each ribosome will 
associate with four copies of the Sec61 complex, and both the ȕ-subunit and the 
ribosome are thought to play a part in that interaction. The Į- and Ȗ-subunits are 
thought to constitute the core of the channel through the ER membrane, with a helical 
segment of the Į-subunit functioning as a removable plug on the lumenal side of the 
ER (see fig 9). At the cytosolic side the ribosome-Sec61 complex association likely 
has a permanent opening for the exit of hydrophilic sections of a transmembrane 
protein. When a sufficiently long and hydrophobic sequence arrives in the 
translocation channel, a lateral gate opens and the hydrophobic segment is moved 
into the lipid phase of the membrane [50]. The fully translated and properly folded 
protein is then transported from the ER membrane by a pathway including formation 
of membrane vesicles [54], through intracellular compartments like ER-Golgi 
intermediate compartment (ERGIC), the cis/medial/trans-Golgi apparatus and the 
trans-Golgi network (TGN) on its way to the cell surface [55]. During or immediately 
after translocation, receptors with the consensus sequence NxS/T can have 
carbohydrates attached to its asparagine (N) in what is called N-linked glycosylation 
[56].   
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Figure 9. Schematic illustration of synthesis and translocation of transmembrane 
proteins into the ER membrane by a ribsosome and the Se61 complex/translocation 
channel. The removable plug regulating transport into the lumen is depicted in blue, while 
lateral transport of transmembrane segments into the lipid phase is not shown. Taken from 
[50]. 
1.2.3 The basic features of signal peptides 
The cleavable signal sequence, i.e. the signal peptide, can be divided into three 
distinct regions based on the properties of the amino acids [57]. The basic design of a 
signal peptide with the three “n”, “h” and “c” regions can be seen in figure 10. 
Figure 10. The basic design of signal peptides with the three regions and cleavage 
site indicated. Modified from the figure presented by Gunnar von Heijne [57].
Starting adjacent to the N-terminal methionine there is a positively charged n-region, 
usually 1-5 amino acids long including positively charged lysine or arginine residues. 
This region seems to be important for the topological positioning of the signal peptide 
and thereby ultimately of the N-terminus of the receptor. However, positive charge is 
not an absolute requirement, as receptor constructs equipped with signal peptides 
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lacking positive charge except for the N-terminal methionine, or even having a 
negative charge in this region, may still express mature proteins. Next there is a 
hydrophobic stretch termed the h-region, usually 7-15 amino acids long, that is 
critical for the signal peptide function. Although mutations leading to charged 
residues in this area don’t necessarily lead to non-expressed proteins, it does severely 
disrupt the expression efficiency for the protein. Conversely, export-defective 
proteins with a disrupted h-region have been shown experimentally to obtain an 
increase in trafficking to the plasma membrane after mutations have increased the 
hydrophobicity or extended this region [57]. The third region is characterized by a 
more polar carboxy-terminal domain consisting of 3-7 amino acids, and is termed the 
c-region. This region specifies where, and if, the signal peptide is cleavable, as it is 
here the signal peptidase enzyme will act. A general rule is that the positions -1 and -
3 are particularly important for determining the cleavage site, the so-called “(-3,-1)-
rule” [57]. The amino acid in position -1 must be small, essentially alanine, serine, 
glycine, cysteine, threonine or glutamine. In the -3 position the amino acid must not 
be aromatic, charged or polar. In addition to these restraints on positions -1 and -3, 
proline must be absent from position -3 through +1[58]. By systematically 
exchanging amino acids in this region, studies have shown that it is possible to induce 
new cleavage sites, and in fact produce proteins with two cleavage sites where 
cleavage occurs to varying extent at both sites [57]. 
1.2.4 Protein prediction software: Signal P and TMHMM 
In order to optimize experimental studies as well as avoiding unnecessary laboratory 
work, the development of advanced computer software predicting protein localization 
has emerged. Utilizing the known features of signal peptides as described above, it is 
possible to analyze N-terminal sequences with this kind of software [59]. One such 
tool is the Signal P software, which is publicly available via the Center for Biological 
Sequences Analysis (CBS) at the Technical University of Denmark. The software is 
still evolving from the first version published in 1997 [60], through its current (as of 
2014) version Signal P 4.1. Earlier versions are still available online for use. The 
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third installment of the software, SignalP 3.0, improved the prediction of signal 
peptides [61] by further developing a method termed the hidden Markov model [62]. 
In SignalP 3.0 the software can perform analyzes using both the hidden Markov 
model and the neural networks model, and presents both results. Later versions of 
SignalP do not use the hidden Markov model, and only present the results using a 
neural networks method. The result of the prediction analysis will indicate whether 
the protein has a signal anchor, a signal peptide, or if it is a non-secretory protein. It 
displays the result as probability of either signal anchor or signal peptide, as well as 
propose cleavage sites for the signal peptide. There is the possibility of false 
negatives as well as positives, and especially relevant in the context of analyzing the 
N-terminal of GPCRs is the possibility that the software confuse the first 
transmembrane segment for a signal peptide. To avoid this mistake the proteins 
transmembrane helices can be predicted by using the TMHMM Server also available 
at the CBS webpage [59]. Examples of such false positives are muscarinic 
acetylcholine receptor M1 and dopamine receptor D1, where an uncritical analysis of 
the first 70 amino acids from the N-termini yields predicted signal peptides with 
cleavage sites proposed at the C-terminal end of the first transmembrane segment 
(cases marked with * in table 1). This highlights the importance of taking into 
consideration the known features of the actual analyzed protein, such as the 7TM 
structure for GPCRs. If the protein that is investigated is more obscure with unknown 
features, the risk of misinterpretations makes it even more important to use the 
predictive theoretical information in tandem with experimental data from the 
laboratory.  
Most GPCRs utilize their first transmembrane domain as a signal anchor, and only 5-
10% of GPCRs are estimated to contain cleavable signal peptides [53]. It is estimated 
that all receptors in the Secretin (class B) [63] and the vast majority in the Glutamate 
(class C) [51] contain signal peptides. Within the Rhodopsin family (class A) the vast 
majority of the glycoprotein hormone receptors (subgroup 1C) contain signal 
peptides. For the luteinizing hormone (LH) receptor it has been shown that inherited 
mutations in the signal peptide sequence can result in non-cleavage [64]. This will 
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lead to a reduced expression of functional receptors, and if both parents have LH-
inactivating mutations male children will have female phenotype and male 
pseudohermaphroditism. For the other two Rhodopsin family subgroups, the 
receptors with small-molecule (1A) and peptide (1B) ligands, signal peptides are 
thought to be a rare occurrence [51]. A common feature of the signal peptide 
containing GPCRs is the size of the N-terminus ectodomain [53, 63]. The monoamine 
GPCRs have in general short N-termini, which in this context should rule out the 
presence of signal peptides, and to our knowledge no monoamine GPCR have 
previously been demonstrated to possess a signal peptide. These receptors will rather 
use the first transmembrane segment as a signal anchor in the translocation of the 
receptor across the ER membrane. Despite this general rule, the monoamine GPCRs 
Į2C and 5-HT2C are predicted to possess signal peptides when analyzed in Signal P 
3.0, as can be seen in table 1. If verified with experimental data, this has implications 
for the structure of these drug targets at the cell surface. For the 5-HT2C receptor the 
presence of a functional 32 amino acid long signal peptide, would mean the mature 
receptor expressed at the cell surface lacks the region where the SNP Cys23Ser is 
situated. In addition, the presence of a signal peptide will influence the expression 
level of the receptor at the plasma membrane. In the future, perhaps ligands that bind 
to the cleavage site of the signal peptide may inhibit its cleavage, and thereby 
decrease the expression of functional receptors at the plasma membrane. The Į2C- as 
well as the Į1D-adrenoceptor are poorly expressed at the plasma membrane. It’s been 
previously shown that the expression levels of the Į1D-adrenoceptor can be elevated 
10-fold by adding a known signal peptide to its N-terminus [65]. This indicates that 
the unusually long, 95 amino acids, N-terminal tail of the wild type Į1D-adrenoceptor 
is an obstacle in efficient translocation, since the long N-tail hinders the first 
transmembrane helix from acting efficiently as a signal anchor. Considering the 
results from the signal peptide prediction and the potential of the Į2C and 5-HT2C
receptors as drug targets, the Į2C-adrenoceptor and the 5-HT2C-receptor were prime 
candidates for our present investigations regarding the functional relevance of the N-
termini of these two receptors.  
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Figure 11. When analyzing the 5-HT2C receptor N-terminus in SignalP 3.0 using the 
hidden Markov model the result is also presented in graphic form like this plot. The 
probability score for each of the three signal peptide regions (green, blue and magenta) as 
well as probability of cleavage at suspected sites (red) can be seen. In this instance the 
sequence of the first 70 amino acids starting from the N-terminus has been analyzed. The 
result predicts cleavage at position 33, i.e. the preceding 32 amino acid sequence is 
predicted to be absent from the mature receptor. 
Signal peptide analysis of selected GPCRs. A step-by-step procedure for 
investigating selected GPCRs for presence of signal peptides can be as follows: a) 
Find the receptor in question at Missouri S&T cDNA Resource Center’s website 
www.cdna.org. b) Copy the Genbank accession number (ACC#). c) Enter accession 
number in the search box at the ncbi databank at www.ncbi.nlm.nih.gov/nuccore/. 
(Step a-c can be substituted by finding the receptor at IUPHARs website 
www.guidetopharmacology.org and clicking the accession number hyperlink) d) 
Copy the amino acid translation of the gene. e) Test an appropriate length of the 
translation beginning from the N-terminus in the Signal P 3.0 prediction software at 
www.cbs.dtu.dk/services/SignalP-3.0/.   
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GPCR SignalP 3.0-HMM 
result 
Accession 
number 
Predicted 
cleavage 
site 
GPCR Class 
and ligand 
 Signal 
peptide 
PRBLTY 
Signal 
anchor 
PRBLTY 
   
Į2A 0.022 0.974 NM_000681.3 Anchor A/monoamine 
Į2C 0.995 0.004 AY455666 22/23 A/monoamine 
5-HT2A 0.000 0.116 NM_000621 Non-
secretory 
A/monoamine 
5-HT2C-Cys23 0.858 0.057 NM_000868 32/33 A/monoamine 
5-HT2C-Ser23 0.831 0.060 NM_000868 
but Cys > Ser 
32/33 A/monoamine 
5-HT2C-3x HA-
tagged 
0.000 0.000 28 a.a. insert 
after start-Met 
Non-
secretory 
A/monoamine 
Į1D 0.002 0.005 NM_000678 Non-
secretory 
A/monoamine 
Į1D-SP 0.962 0.015 16 a.a. SP 16/17 A/monoamine 
M1*  (0.378) (0.331) AF498915 42/43 
(false) 
A/monoamine 
M2 0.007 0.874 AF498916 Anchor A/monoamine 
D1* (0.530) (0.442) NM_000794 46/47 
(false) 
A/monoamine 
D2 0.000 0.943 NM_000795 Anchor A/monoamine 
Corticotropin-
releasing factor 
(CRF) receptor 1 
0.986 0.000 AY457172 23/24 A/peptide 
CRF receptor 2 0.852 0.000 AY449734 19/20 A/peptide
Endothelin 
receptor type B 
0.999 0.001 AY275463 26/27 A/peptide 
μ opioid receptor  0.001 0.538 AY521028 Anchor A/peptide 
Cannabinoid 1 
(CB1) receptor 
0.000 0.000 NM_016083 Non-
secretory 
A/lipid 
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GPCR SignalP 3.0-HMM 
result 
Accession 
number 
Predicted 
cleavage 
site 
GPCR Class 
and ligand 
 Signal 
peptide 
PRBLTY 
Signal 
anchor 
PRBLTY 
   
CB2 receptor 0.000 0.274 AY242132 Non-
secretory 
A/lipid 
FSH receptor 1.000 0.000 AY429104 17/18 A/glycoprotein 
Calcitonin 0.998 0.000 AY430048 24/25 B/peptide 
Secretin 1.000 0.000 AY462218 27/28 B/peptide 
GABA B2 1.000 0.000 NM_005458 41/42 C/amino acid 
Metabotropic 
glutamate 2   
1.000 0.000 NM_000839 18/19 C/amino acid 
BAI1  1.000 0.000 NM_001702 30/31 Adhesion/ 
Phosphatidyl-
serine 
WNT receptor 
frizzled-4 
1.000 0.000 AY462097 36/37 Frizzled/protein
Table 1. A selection of G-protein coupled receptors analyzed with the signal peptide 
prediction software SignalP 3.0 using the hidden Markov model. The first 70 amino 
acids, counting from the N-terminus, were analyzed for all receptors. Presented is the 
calculated probability of the receptor having either a signal peptide or signal anchor, and for 
the predicted signal peptides the most likely cleavage point. A flaw in the software is 
highlighted by some well characterized GPCRs that are predicted to be non-secretory, like 
the cannabinoid receptors CB1 and CB2. Also, when analyzing muscarinic acetylcholine 
receptor M1 and dopamine receptor D1 the software misinterprets the first transmembrane 
segment for a signal peptide, and proposes a cleavage site within the first transmembrane 
segment. To denote this mishap M1 and D1 have an asterisk by them and the results are in 
brackets. Class A = Rhodopsin family, Class B = Secretin family, Class C = Glutamate 
family, PRBLTY = probability, HMM = hidden Markov model, SP = signal peptide, FSH = 
follicle-stimulating hormone. 
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2. AIMS OF THE PRESENT STUDY 
G-protein coupled receptors that are activated by the monoamine type of endogenous 
ligands generally have short N-termini, and use their first transmembrane segment as 
a reverse signal anchor during cotranslational translocation of the receptors into the 
endoplasmic reticulum membrane. When analyzing the N-termini of the 5-HT2C
receptor and Į2C-adrenoceptor the protein prediction software Signal P 3.0 concludes 
that they likely have signal peptides. This is surprising, since these two receptors are 
the only monoamine GPCRs predicted to have signal peptides. The presence of such 
signal peptides would have implications for the structure of the mature receptors and 
for the evaluation of the role of the N-tails at these receptors, which both are 
considered promising future drug targets. The 5-HT2C receptor has a single nucleotide 
polymorphism within the putative signal peptide sequence. This polymorphism has 
been proposed to be associated with diverse clinical consequences. The Į2C-
adrenoceptor is poorly expressed at the cell surface, while displaying a considerable 
intracellular pool. This is in contrast to the Į2A-adrenoceptor which is well expressed 
at the cell surface, and which share a highly conserved amino acid sequence with Į2C, 
with the exception of the N-tail and the third intracellular loop.      
The principal aims of the present project were to: 
i) Determine if the 5-HT2C receptor has an N-terminal signal peptide with cleavage 
site after 32 amino acids. 
ii) Determine if the Į2C-adrenoceptor has an N-terminal signal peptide with cleavage 
site after 22 amino acids. 
iii) Rebuilding the N-terminal tail of the 5-HT2C receptor, as well as that of the Į2C-
adrenoceptor, for investigating the influence of the N-terminus on the expression 
level of these two receptors at the plasma membrane. 
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iiii) Create chimeras of the Į2A- and Į2C-adrenoceptors for investigating what parts of 
the Į2C-adrenoceptor are responsible for: a) its poor expression level at the plasma 
membrane, and b) for the Į2C-binding-selectivity of ligands. 
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3. SUMMARY OF RESULTS (PAPERS I, II AND III) 
3.1 PAPER I 
The N-terminal region of the human 5-HT2C receptor has a cleavable signal 
peptide. 
The principal aim of this paper was to determine if the human 5-HT2C receptor has a 
cleavable signal peptide in its N-terminus. This task was performed by engineering 
receptor constructs containing an eight amino acid long epitope (FLAG), transiently 
transfecting COS-7 cells and immunostaining the expressed receptor constructs with 
the selective antibody M1. The M1 antibody binds to the FLAG epitope only when 
the epitope is the outmost N-terminal part of the protein. Thereby, inserting the 
FLAG epitope after the predicted cleavage site makes cleaving detectable by the M1 
antibody. The M2 antibody used as control binds to the FLAG epitope regardless of 
its position in the N-terminus. The 5-HT2C receptor has been shown to have a 
prevalent single nucleotide mutation in its N-terminus where 13% of the Caucasian 
population has a serine instead of cysteine (Cys23Ser). When analyzing the N-
terminus sequence in the protein prediction database SignalP, the results show that 
the outermost 32 amino acids in its N-terminus are predicted to be cleaved off. This 
made us interested in validating the prediction results experimentally. At first this 
was done by checking if the M1 and M2 antibodies were binding to our constructs by 
qualitative investigation with epifluorescence microcopy. The receptor construct 
modelling for the wild type receptor (5-HT2C-B), i.e. where the only modification was 
incorporating the epitope immediately downstream of the predicted cleavage site, 
resulted in positive staining with the selective antibody M1 (5-HT2C-B  in table 2, 
paper I). Receptor densities in COS-7 membranes determined by radioligand binding 
with [3H]-mesulergine, were also quantified for all ten engineered constructs. Every 
binding experiment also contained the wild type receptor with its receptor density set 
to 100%, and the simultaneously determined densities for the constructs were 
normalized to the wild type value. The relative expression levels of binding 
competent receptor constructs supported the qualitative result obtained with 
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epifluorescence, which indicate that the receptor has a functional signal peptide, as 
hindering cleavage of the putative signal peptide resulted in a relative expression 
level of only 30% (construct nA in table 1 and figure 3, both in paper I).  
Figure 12. Relative expression levels of wild type 5-HT2C receptor and engineered 
receptor constructs. Bar chart is showing binding competent 5-HT2C receptors in cell 
membranes after transient transfection of COS-7 cells, with values normalized to that of the 
wild type receptor. In paper I, figure 1, an overview of the receptor constructs are shown. 
This figure is taken from paper I.   
To verify the results from epifluorescence and radioligand binding experiments, the 
immunostaining protocol was optimized for confocal imaging. In addition to 
validating the previous results (panel a in figure 1, paper I), the confocal imaging 
experiments also quantified the fluorescence intensity across the cell (panel e and f in 
figure 1, paper I), thus confirming that we were visualizing receptors expressed at the 
cell surface. The main conclusion of these experiments is that the human 5-HT2C
receptor N-terminus has a 32 amino acid long cleavable signal peptide. Consequently 
the mature receptor does not contain the aforementioned Cys23Ser mutation. 
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3.2 PAPER II 
The predicted N-terminal sequence of the human Į2C-adrenoceptor does not act 
as a functional cleavable signal peptide. 
The principal aims of this paper was to determine if the human Į2C-adrenoceptor has 
a cleavable signal peptide (SP) in its N-terminus, and to what extent the N-terminus is 
contributing to the low expression levels of the receptor. As in paper I, investigating 
the presence of the predicted cleavable signal peptide was achieved by engineering 
among others a receptor construct containing the FLAG epitope immediately after the 
predicted cleavage site in the N-terminus, transiently transfecting COS-7 cells and 
immunostaining the expressed receptor constructs with the selective antibody M1. It 
became evident in the preliminary qualitative investigation with epifluorescence 
microscopy that the receptor construct equipped with FLAG epitope after the 
predicted signal peptide sequence of the wild type (Į2C-3 in table 2 in paper II) 
exhibited no staining, i.e. suggesting the predicted signal peptide was not cleaved off. 
This result was confirmed when the experimental protocol was optimized for 
investigations with confocal microscopy. As can be seen in figure 4 in paper II, the 
staining was negative when Į2C-3 was stained with the selective antibody M1 (panel 
A) while positive when staining with the M2 antibody control (panel B). For the 
cleavage control construct, Į2C-5, which has the established influenza hemagglutinin 
signal peptide (HAsp), both M1 and M2 showed positive staining (panel C and D). In 
panel E and F in figure 4, the presence of the receptors at the cell surface was 
confirmed by measuring the fluorescence intensity across a cell expressing the 
control construct Į2C-5. Consequently, the results show that the 22 amino acid long 
putative endogenous signal peptide is indeed not cleavable, in contrast to the 
prediction. 
To investigate to what extent the N-terminus is contributing to the low expression 
levels of the receptor; eight additional receptor constructs without FLAG epitope 
were engineered. These constructs are presented schematically in figure 1 in paper II, 
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and are termed: 2, 4 and 8-13. Construct 2 contains a known cleavable signal peptide 
instead of the putative endogenous signal peptide, while in construct 4 the known 
signal peptide is inserted before the full length wild type receptor. This known signal 
peptide is the above mentioned influenza hemagglutinin signal sequence (HAsp), 
which has previously been shown to enhance the expression of Į1D- and ȕ2-
adrenoceptors [65, 66]. Construct 13 has a lysine inserted at amino acid position 3, in 
an attempt to increase the positive charge of the n-region of the putative signal 
peptide. A more positively charged n-region could increase the efficiency of 
translocation [57] and thereby increase the expression level. The remaining constructs 
(8-12) are to varying degree truncated at the N-terminus, which is a maneuver 
previously shown to enhance the expression of Į1D-adrenoceptors [65]. Among the 
receptor constructs without interfering FLAG epitope, constructs 4 (wild type with 
added HAsp) and 13 (improved endogenous SP) have the same expression levels as 
the wild type, while the remaining constructs (2 and 8-12) have 50% or less relative 
expression of binding competent receptors when normalized to the wild type. Figure 
3 from paper II with the relative expression levels of the receptor constructs 
normalized to the wild type is shown below.  
Figure 13. Expression levels of wild type Į2C-adrenoceptor and 12 constructs with 
modified N-terminus. Bar chart displaying the Bmax-values normalized relative to the wild 
type Į2C-adrenoceptor. Receptor constructs 3, 5, 6 and 7 have FLAG epitope. Taken from 
paper II [34]. 
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Consequently, the results show that the endogenous N-terminus of the Į2C-
adrenoceptor is not fully responsible for the low expression levels of the receptor, but 
rather is a necessary component for the receptor to be well expressed. This suggests 
the truncated receptors are not capable to compensate for their deleted N-tail stretches 
by efficiently utilizing the first transmembrane segment as a signal anchor. See for 
example the poorly expressed construct 12, where the majority of the N-terminus is 
truncated. It is especially interesting that none of the two constructs containing the 
influenza hemagglutinin signal sequence (2 and 4) had increased expression. This 
means that among our tested constructs the endogenous N-terminus is optimal for 
expression of the Į2C-adrenoceptor.   
3.3 PAPER III 
The aims in this paper were two-fold: a) Continuing the investigations from paper II 
into which part of the Į2C-adrenoceptor is responsible for the low expression levels of 
the receptor, and b) Investigate what parts of the Į2A- and Į2C-adrenoceptor subtypes 
are most important for drug selectivity between them. In particular investigating 
whether transmembrane region 1 (TM1) and extracellular loop 2 (ECL2) have a 
general effect on the affinity for “bulky” drugs at the Į2A-adrenoceptor. To achieve 
these aims six Į2A/Į2C-adrenoceptor chimeras were constructed, the chimeras and the 
wild type receptors were transiently transfected to HEK293 cells, and the receptor 
densities in the resulting membrane preparations were determined by radioligand 
binding. A schematic representation of the chimeric Į2A/Į2C-adrenoceptors can be 
seen in figure 2 in paper III, while the specific conserved amino acids where the 
chimeric regions are spliced together are shaded in figure 3 in the paper (i.e. “YS”, 
“TS” and “PP”). These amino acids are also part of the names given to the receptor 
constructs.  
To compare the N-termini’s influence on the expression levels, two of the six 
chimeras had the wild type N-termini preceding the conserved YS-motif exchanged, 
creating the CysA and AysC chimeras. The expression levels were normalized 
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relative to the wild type Į2A-adrenoceptor, and are presented in table 1 in paper III 
[67]. The data from table 1 in paper III is presented below in a bar chart (figure 14).  
Figure 14. Expression levels of wild type Į2A- and Į2C-adrenoceptors and six chimeric 
constructs. Relative Bmax expression levels of binding competent wild type Į2A- and Į2C-
adrenoceptors and six Į2A/Į2C-adrenoceptor chimeras, normalized to the wild type Į2A-
adrenoceptor. The figure is depicting the data published in table 1 in paper III [67]. 
While the wild type Į2C-adrenoceptor had a relative expression level of about 23% 
compared to Į2A, the chimeric receptor containing the N-terminus from Į2A-
adrenoceptor (AysC) only had 12%. This indicates that the Į2A-adrenoceptor N-
terminus could not overcome the low expression levels of the wild type Į2C-
adrenoceptor. The other chimeric receptor constructs focus on the influence of the 
Į2C-adrenoceptor N-terminus and TM1 region (CtsA), TM2-TM4 region (AtsCppA) 
and the C-terminal half of the receptor (CppA and AppC). As can be seen in figure 
14, the CtsA and AtsCppA chimeras’ expression levels are comparable to the wild 
type Į2A-adrenoceptor, at about 97% and 89% respectively. These two constructs 
have their C-terminal half taken from Į2A. The lack of expression-modifying effect 
seems to rule out that the N-terminus and TM1 or TM2-TM4 regions, which in these 
chimeras are derived from Į2C, have significant impact on the expression level of the 
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wild type Į2C-adrenoceptor. Supporting these observations that the N-terminal half of 
the Į2C-adrenoceptor does not have a negative effect on the expression of the 
chimeric receptors, the AppC construct, having the C-terminal half taken from Į2C, is 
as poorly expressed as the wild type Į2C-adrenoceptor. Consequently, the C-terminal 
half of the receptor determines the Į2C-adrenoceptor low expression levels at the cell 
surface. 
  
In addition to the wild type Į2A- and Į2C-adrenoceptors, the chimeras AppC, CppA, 
CtsA and AtsCppA were used to investigate if the TM1 and ECL2 have a general 
effect on the affinity for “bulky” drugs at the Į2A-adrenoceptor as proposed by Laurila 
et al [68]. These chimeras are the same ones as described above (figure 2 and 3 in 
paper III), and represent the three regions: i) N-terminus-TM1, ii) TM2-TM4 and iii) 
the C-terminal half from ECL2 onwards. The affinities of seven different ligands 
were determined for the wild type receptors and for the chimeras. Spiroxatrine, 
clozapine, spiperone, MK912 and chlorpromazine are all fairly “bulky” Į2C-selective 
ligands, while atipemazole is rather non-selective and BRL44408 is Į2A-selective. In 
table 2 the resulting drug affinities are presented with pKi values and the drug’s Ki
ratios at Į2A versus the other receptor constructs. Analyzing the results in the table 
three patterns emerge: 1. Spiroxatrine and MK912 showed high affinity for Į2C and 
AppC, i.e. the C-terminal half of the receptor is the region determining the drug’s 
affinities. 2. Spiperone and clozapine showed the highest affinity for receptors 
containing the C-terminal half of Į2C, but also intermediate affinities for constructs 
were the TM2-TM4 region was derived from Į2C. 3. Of the five Į2C-selective ligands 
tested, only chlorpromazine showed higher affinity for CtsA than for wild type Į2A, 
i.e. the TM1 region of Į2A contribute to the low affinity of chlorpromazine, but not 
spiroxatrine, clozapine, spiperone or MK912 at Į2A as compared to CtsA. The 
consequence of these results is that the TM1 and ECL2 regions of the Į2A-
adrenoceptor do not have a general effect on the affinity for “bulky” drugs at the Į2A-
adrenoceptor.        
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4. GENERAL DISCUSSION 
4.1 METHODOLOGICAL CONSIDERATIONS 
The results obtained in paper I, II and III are all based on the same methodological 
concepts: Rebuilding the wild type receptors by PCR and transiently expressing the 
mutated receptors in mammalian cell lines COS-7 (papers I and II) and HEK293 
(paper III). The receptor constructs expressed at the cell surface are then investigated 
by immunofluorescence and/or radioligand binding. The radioligand binding 
experiments are used as a control, in order to determine the expression levels of the 
receptor constructs that were used in the immunostaining experiments, which, in turn, 
were performed for investigating the presence of signal peptides. In addition to this 
the radioligand binding experiments are an independent tool with regard to 
investigating different receptor construct’s efficiency at being expressed at the plasma 
membrane, by measuring receptor densities in membrane preparations and whole 
cells. The presence of ligand binding receptors expressed after transfection are chosen 
as the experimental end-point measurement, presumably reflecting the efficiency of 
the integration of the receptor into the ER membrane, as this is the critical point when 
investigating N-terminal function of these receptors. All the radioligand binding 
experiments include the wild type receptors in addition to the engineered constructs.  
In paper I, investigating the 5-HT2C-receptor, 10 new constructs were engineered to 
investigate for the presence and cleavability of the putative signal peptide and its 
relevance for expression. Seven of the constructs contain an epitope for 
immunostaining, while three constructs are purely for investigation with radioligand 
binding.  
In paper II, investigating the Į2C-adrenoceptor for a cleavable signal peptide and the 
N-terminus’ effect on expression levels, 12 new constructs were engineered. Four of 
the constructs contained an epitope for immunostaining, while the remaining eight 
48
constructs are purely for investigating receptor densities at the cell surface with 
radioligand binding.  
In paper III, six chimeric Į2A-/Į2C-adrenoceptor constructs were engineered to 
investigate expression levels as well as drug subtype selectivity. Consequently none 
of these receptors are encoded with the epitope, and they are exclusively investigated 
with radioligand binding.  
As the choice of expression vector and cell line can have a significant impact on 
protein production [69] all 5-HT2C constructs are expressed with pcDNA3.1+ in 
COS-7 cells, while the Į2C-adrenoceptor constructs in paper II are expressed with 
pCi-neo in COS-7 cells and all constructs in paper III with pcDNA3.1+ in HEK293 
cells. By doing this we ensured that the results could be normalized to the wild type 
receptor for each set of experiments. 
4.1.1 Investigating N-termini for signal peptide function with the 
FLAG epitope 
To investigate whether the putative cleavable signal peptides of the 5-HT2C and Į2C
receptors in fact are cleaved, we decided to use the well-established technique of 
building receptor constructs with the encoded FLAG epitope inserted in the N-
terminal [70]. The FLAG epitope is an eight amino acid long sequence: 
DYKDDDDA [66]. Transiently transfecting mammalian cell lines like COS-7 and 
HEK293 works as a model for how the wild type receptor might work in vivo [71]. 
The FLAG epitope is encoded in the N-termini at the position where the putative 
cleavage site is proposed, thereby being the first sequence of the mature receptor if 
the putative signal peptide is cleaved. The epitope is recognized by a selective 
primary antibody (M1) that will only bind to the epitope if it is the absolute N-
terminus of the receptor. Even the presence of a single methionine encoded by the 
start codon in front of the FLAG epitope is enough to prevent binding of the M1 
antibody [70]. By labeling the selective antibody with a fluorescent secondary 
49
antibody, it is possible to visualize the cleaving of the putative signal peptide with 
fluorescent microscopy. A non-selective primary antibody (M2) that recognizes the 
epitope regardless of its position in the N-terminus, acts as necessary control to 
ensure that the epitope-tagged receptor is expressed at the cell surface and can be 
visualized, independent of whether or not the FLAG epitope has become outmost N-
terminal by cleavage of the signal peptide. An alternative strategy could have been to 
label the primary antibodies M1 and M2 with fluorescent probes, making the use of 
labeled secondary antibodies unnecessary. However, secondary antibodies offer 
increased sensitivity through the signal amplification that occurs as multiple 
secondary antibodies bind to a single primary antibody. In addition, exactly the same 
amount of the secondary antibody can be added to M1 and M2 treated samples, 
making background fluorescence identical for the two samples.    
Although the technique is well-established, it is necessary to ensure that this model 
indeed approximates the in vivo function of the receptor. This necessitates the 
engineering of receptor constructs other than the wild type receptor with inserted 
FLAG epitope. This includes both negative and positive controls for the primary 
antibodies, as well as controls to ensure the epitope itself does not have an impact on 
the N-terminal function and subsequently expression of the receptors. The complete 
lists of 5-HT2C receptor and Į2C-adrenoceptor constructs investigated can be seen in 
figures 1, in paper I and II respectively. Positive control constructs, are represented 
by constructs having a known cleavable signal peptide instead of the putative 
endogenous signal peptide, with the cleavage site immediately prior to the epitope. 
This method has previously been described by Kobilka and co-workers for studies on 
the ȕ2-adrenoceptor [66]. In the studies presented in papers I and II, we use both the 
same signal peptide sequence from influenza hemagglutinin [72] as well as the same 
epitope as Kobilka’s group.  
The epitope-tagged receptor constructs were investigated by epifluorescence 
microscope, which gave us a qualitative result, i.e. positive staining or not. The 
experiments were performed on cells without permeabilization, as it is the mature 
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receptors expressed at the cell surface that is of interest to us. Then we wanted to 
verify that the fluorescence we could see in the epifluorescence microscope indeed 
was at the cell surface. This was performed by optimizing the techniques used for the 
epifluorescence microscope, and visualizing the results in a confocal fluorescence 
microscope. By using a confocal microscope it is possible to visualize the 3D 
structure of the cell, optically slice-by-slice, from the outermost point of the cell 
surface through the interior to the cell surface on the opposite side of the cell. By 
measuring the fluorescent intensity across one such section of a cell it is possible to 
quantify the difference in fluorescence intensity from the cell membrane to the 
interior of the cell. This is not meant as a method to exclude the presence of 
intracellular receptors, as the receptors were not permeabilized, but to verify that we 
are observing receptors localized to the cell surface.   
4.1.2 The N-terminus relevance for expression of cell surface 
receptors 
Whether the 5-HT2C receptor and Į2C-adrenoceptor have cleavable signal peptides or 
not, their N-termini’s relevance for expression levels of the receptors are worth 
investigating. This is because the presence of a hydrophobic stretch, which is present 
within the N-tail of these two receptors, clearly is an unusual feature within the 
monoamine class of GPCRs. By engineering constructs with truncated N-terminal tail 
[65, 73], or with the addition of the aforementioned signal peptide sequence from 
influenza hemagglutinin at the N-terminus [65, 66, 73], receptor densities at the 
plasma membrane have been greatly enhanced for the Į1D- and ȕ2-adrenoceptors and 
the cannabinoid receptor CB1. A different cleavable signal peptide named the 
LRRC32 signal peptide, or Lucy tag, has recently been shown to enhance the cell 
surface expression of olfactory GPCRs in HEK293T cells when positioned at the N-
terminus [12]. Research on these receptors have been hindered by their low or non-
existent cell surface expression in cell lines, so this method of increasing expression 
without changing the structure of the mature receptor could accelerate our knowledge 
of this very large group of GPCRs. The constructs used in the here presented studies, 
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to reveal the role of the N-terminal tails of the 5-HT2C- and Į2C-receptors, are 
described in the following sections.  
4.1.3 The 5-HT2C receptor N-terminus’ influence on expression 
The major aim of investigating the 5-HT2C receptor was determining whether the 
predicted signal peptide is present and thereby the presence of the single nucleotide 
polymorphism Cys23Ser in the mature receptor. Consequently the constructs 
designed for this receptor focuses on changes related to the putative signal peptide. 
Constructs include clones with the endogenous signal peptide exchanged for the 
influenza hemagglutinin signal peptide (5-HT2C-E in figure 1 in paper I), truncated at 
the proposed cleavage site (5-HT2C-D in figure 1 in paper I), and with single mutation 
to induce non-cleavage (5-HT2C-nA and 5-HT2C-nB in figure 1 in paper I).Thereby, 
we could detect whether the predicted signal peptide could be cleaved, detect the 
expression level of the receptor when the putative signal peptide was deleted and the 
expression level of the receptor when the putative signal peptide could no longer be 
cleaved off.  
4.1.4 The Į2C-adrenoceptor N-terminus’ influence on expression 
Considering the low expression level of the Į2C-adrenoceptor and significant 
intracellular location, several constructs were made in an attempt to increase the 
expression of mature ligand binding receptors at the cell surface. The engineered 
constructs are analogous to earlier successful expression-enhancing changes made on 
the Į1D-adrenoceptor, ȕ2-adrenoceptor and CB1 cannabinoid receptor [65, 66, 73]. 
This includes various truncations of the N-terminus, in addition to adding the 
influenza hemagglutinin signal peptide to both the wild type receptor and instead of 
the putative endogenous signal peptide. Due to the large intracellular pool of Į2C-
adrenoceptors, we performed radioligand binding studies not only on membrane 
preparations, but also on whole cells and matching membrane preparations (paper II). 
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By doing the experiments with whole cells and matching membrane preparations, we 
could determine if intracellular Į2C-adrenoceptors were binding-competent and to 
what extent they might influence the saturation experiments of membrane 
preparations. The Į2A-adrenoceptor is efficiently expressed at the cell surface and has 
negligible intracellular location, and was used as a model to compare binding to cell 
surface receptors versus total membrane receptors (including intracellular receptors). 
In paper III, the N-terminus as well as the first transmembrane helix (TM1), the 
second to fourth transmembrane helix (TM2-TM4) and the C-terminal half of the Į2C-
adrenoceptor, were further investigated with regard to relevance for expression levels. 
These investigations used the Į2A-adrenoceptor as a model, and the receptor 
constructs are chimeras of the Į2C- and Į2A-receptors. Thereby we could detect what 
parts of the Į2C-adrenoceptor had the largest impact for the lower expression level of 
the Į2C-adrenoceptor compared to the well-expressed Į2A-adrenoceptor.   
4.1.5 Which region of the Į2C-adrenoceptor determines selectivity 
for  “bulky” drugs 
Scheinin and co-workers investigated the possible role of the N-terminus and first 
transmembrane domains of Į2-adrenoceptors on drug subtype selectivity of “bulky” 
drugs like spiroxatrine and chlorpromazine, that are Į2C-/Į2B-selective over Į2A-
adrenoceptors. This was done by combining chimeric receptor constructs and 
radioligand binding with receptor modelling [68]. Their conclusions included that the 
first transmembrane domain of the Į2A-adrenoceptor has an indirect effect on receptor 
conformation, and thereby decreasing the binding affinity of “bulky” drugs at the 
wild type Į2A-adrenoceptor. To investigate whether these results could be reproduced 
and generalized to other “bulky” drugs, the wild type Į2C- and Į2A-adrenoceptors and 
chimeras exchanging the TM1, TM2-TM4 and the C-terminal half regions of the 
receptors were investigated for subtype selectivity of seven drugs. Five drugs are 
fairly bulky and Į2C-selective: Spiroxatrine, cloazapine, spiperone, MK912 and 
chlorpromazine. Atipemazole was chosen because it is rather non-selective and 
BRL44408 because it is Į2A-selective. The experiments were performed by transient 
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expression of the receptors in HEK293 cells, followed by [3H]-RX821002 
radioligand binding competition experiments of the tested drugs. The resulting pKi-
values and the calculated Ki-values are used to determine which region(s) of the Į2C-
receptor determines the affinity for the tested drugs. The Ki-values for the individual 
drugs were compared to their Ki-value at the Į2A-receptor, i.e. Į2C-selectivity is 
represented by a ratio of above 1 and Į2A-selectivity by a ratio of below 1. Thereby, 
we could detect how the three investigated regions of the Į2A- and Į2C-adrenoceptors 
influences drug selectivity for the tested ligands.   
4.2 DISCUSSION OF 5-HT2C RESULTS 
4.2.1 The 5-HT2C receptor has a cleavable signal peptide 
The main conclusions from our study of the human 5-HT2C receptor is that it has a N-
terminal 32 amino acid long cleavable signal peptide, which must be cleaved off for 
efficient translocation of the receptor to the membrane. To the best of our knowledge 
this is the first monoamine GPCR identified with a cleavable signal peptide in its N-
terminus. As a consequence the mature receptor expressed at the cell surface does not 
contain the single nucleotide polymorphism Cys23Ser. This mutation occurs among 
13% of the Caucasian population, and is being investigated for relevance regarding 
personal susceptibility to psychiatric disorders and outcome of pharmacological 
treatments.  
As the cleavage of the proposed signal peptide sequence was identified with specific 
immunolabeling, the investigated construct was the wild type receptor modified with 
the inclusion of an epitope. This means of course that it strictly speaking is the 
engineered receptor construct with the FLAG epitope that has been shown to have a 
cleavable signal peptide. There are however supporting evidence for our conclusion. 
Thus, in our investigation of receptor densities in membranes with radioligand 
binding, we show that a very small change, at a very critical site for the functionality 
of the signal peptide, had a dramatic effect on the expression level of the receptor. 
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This was done by changing one amino acid at the end of the putative signal peptide in 
position -1 relative to the cleavage site from alanine to asparagine, and thus cleavage 
at the proposed site should be hindered as per the (-1, -3)-rule [57]. When compared 
to the wild type receptor this single amino acid mutation resulted in a 70% reduction 
of the expression of the receptor. This also implies that the cleavage of the signal 
peptide sequence is essential for efficient translocation of the wild type receptor. The 
signal peptide is however not necessary for expression of the receptor, as the 
construct lacking the 32 amino acids indeed had an increased expression compared to 
the wild type receptor. This suggests that the receptor can in the absence of a signal 
peptide in the N-terminus efficiently utilize the first transmembrane segment as a 
signal anchor. Accordingly, the translocation into the ER of a truncated 5-HT2C 
receptor seems to be transformed from signal peptide-mediated in the wild type 
receptor to signal anchor-mediated when truncated. In support of our conclusion that 
5-HT2C has a cleavable signal peptide is a study into 5-HT2C receptor dimerization 
[74], where amino acid sequencing of the N-terminus  showed it started with amino 
acid 33. Also, earlier work with in vitro mRNA transcription and translation of the 
mouse 5-HT2C receptor followed by gel electrophoresis indicated a cleavable signal 
peptide [75]. 
4.2.2 Incorporating epitopes in the N-terminus influence receptor 
expression 
Even though the FLAG epitope is only eight amino acids long and is incorporated in 
the N-terminus, and engineering constructs with epitopes for immuolabeling is 
widely used in experiments, our results show that such changes can have substantial 
impact on receptor expression. By comparing receptor densities in membranes 
expressing constructs that are differing only by the inclusion of the epitope, it 
becomes obvious that the epitope itself can influence the expression level of the 
receptor. With expression levels normalized relative to the wild type receptor, the 
FLAG epitope situated immediately after the putative signal peptide increased 
expression levels to about 160% (5-HT2C-B in table 1 and figure 1 in paper I). In 
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contrast there was a decrease in expression levels to about 30% when the epitope is 
situated immediately before the putative signal peptide (5-HT2C-G in table 1 and 
figure 1 in paper I). It is obvious that inserting an eptitope before a signal peptide will 
have a large negative impact since the signal peptide is dependent on its consensus n-
h-c structure. For receptors using the first transmembrane segment as a signal anchor 
the negative impact on expression should be less pronounced. This highlights the 
importance of corroborating experimental data gathered by imunolabeling epitope-
incorporated constructs, with data gained by an alternative method such as 
radioligand binding studies to assure that the constructs are well expressed and 
functional. 
4.3 DISCUSSION OF ALPHA2C-ADRENOCEPTOR 
RESULTS 
4.3.1 The Į2C N-terminus does not contain a 22 amino acids long 
cleavable signal peptide 
As we try to elucidate what distinct functional characteristics the Į2C-adrenoceptor N-
terminus might have, we can with confidence say it is unlikely to have a cleavable 
signal peptide with a length of 22 amino acids. However, since the investigated 
receptor construct (Į2C-3 in paper II) does contain the FLAG-binding epitope inserted 
after the putative signal peptide, the downstream environment of the putative signal 
peptide is altered compared to the wild type receptor. On the other hand, the positive 
cleavage control construct, Į2C-5 in paper II, had its hemagglutinin signal peptide 
positioned at the same place as the endogenous putative signal peptide in Į2C-3, and it 
was properly cleaved off. There is also a possibility that the Į2C-adrenoceptor does 
have a cleavable signal peptide in its N-terminus, but with a different cleavage site. 
When analyzing the N-terminus in SignalP 4.1, the latest version of the signal peptide 
prediction software, the N-terminus is predicted to have two possible cleavage sites, 
after amino acid number 15 or 22, with a higher predictive value for position 15/16 
[76]. In addition, the presence of an N-linked glycosylation site at position 19 of the 
Į2C-adrenoceptor makes cleaving after 15 amino acids much more probable than 
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cleaving after 22 amino acids. Further studies outlined in the future perspective 
chapter would be required to confidently conclude whether the Į2C-adrenoceptor after 
all has a cleavable signal sequence, in that case with a different cleavage site, 
presumably after amino acid 15 in its N-terminus. 
4.3.2 The N-terminus is necessary for efficient expression of 
mature Į2C-adrenoceptors  
With a total of 13 Į2C-adrenoceptor constructs investigated in paper II and an 
additional 6 Į2C- and Į2A-receptor chimeras investigated in paper III, the Į2C-
adrenoceptor’s N-terminus is thoroughly investigated with regard to influence on 
expression levels of binding competent receptors. The main conclusion of these 
investigations is that the Į2C-adrenoceptor N-terminus is necessary for efficient 
expression of binding competent receptors. So even though the wild type receptor is 
poorly expressed at the cell surface and the N-terminus is unusually long, all our 
attempts at increasing its expression level by modifying the N-terminus failed. The 
common feature of the receptor constructs that have expression levels comparable to 
the wild type receptor, is that they have an intact endogenous N-terminus.  
In contrast to our conclusions regarding the global effect of the N-terminus on 
expression of binding competent Į2C-adrenoceptors, Angelotti and co-workers have 
proposed that the hydrophobic stretch of the N-terminus is a retention signal 
regulating trafficking of the receptor from the endoplasmic reticulum to the cell 
surface [35]. The differing conclusions regarding the effect of the N-terminus on 
expression of binding competent receptors as determined by radioligand binding are 
striking. A detailed discussion of the different interpretation of our results can be read 
in paper III. While we don’t dispute Angelotti and co-workers results from studying 
the trafficking of epitope-containing receptor constructs, their radioligand binding 
results (table 3 in [35]) are at odds with ours. They seem to have an increase in the 
expression of binding competent Į2C-receptor constructs both by truncating the N-
terminus and by exchanging the parts of the Į2C N-terminus for the Į2A. Whether 
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there are methodological differences is difficult to interpret from the published data, 
especially since their table of radioligand binding data for truncated receptors lack the 
wild type control. Since we are always performing matching transfections and 
radioligand binding experiments and subsequently normalizing the data to that of the 
wild type receptor, the expression levels of the different receptor constructs is easily 
comparable in our data. Another possible extraneous influence on the expression of 
binding competent receptors is the presence of epitopes in the N-terminus of the 
receptor. In their trafficking experiments Angelotti and co-workers use receptor 
constructs containing an epitope in the N-terminus. As we have shown in our study of 
the 5-HT2C receptor the eight amino acid long FLAG epitope incorporated into the N-
terminus can have a substantial impact on the expression levels of the receptor.  
The publication of paper III prompted Angelotti and Hurt to comment on our results 
in a letter to editor [77]. We answered this comment from Angelotti and Hurt in a 
rebuttal letter to the editor [78]. The crux of the disagreement seems to stem from the 
different data on expression of binding competent Į2C-adrenoceptors as determined 
by radioligand binding, since we have not studied trafficking of receptors or 
intracellular location. In support for our radioligand binding data are the work of 
Laurila and co-workers [68], where a chimeric Į2C-adrenoceptor containing the N-
terminus and TM1 from Į2A showed lower expression level than the wild type Į2C-
adrenoceptor. However, as they are using stable transfection of CHO cells, the 
expression levels can be arbitrary depending on the stable transfection process.  
The consensus regarding translocation and regulation of trafficking of GPCRs is that 
the N-terminus and TM1 are important for the transfer of the receptor from the 
ribosome to the ER [79], while intracellular loops and the C-terminal tail are 
important with regard to regulation of trafficking of receptors from the ER to the 
plasma membrane [80]. In support of this general consensus, Motawea and co-
workers recently showed that trafficking of Į2C-adrenoceptors from the Golgi 
compartment to the cell surface was mediated through an arginine-rich (R) region in 
the C-terminus [40].The arginine-rich region is not conserved among the Į2-
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adrenoceptor subtypes, and is only present in the Į2C-adrenoceptor where it includes 
amino acids 454-458, RRRRR, close to TM7. This is in close proximity to the two 
conserved regions among the Į2-adrenoceptor subtypes; NPXXYXXF and 
FXXXFXXXF in the end of TM7 and the very beginning of the C-terminus [40]. The 
NPXXYXXF region is important for the receptor structure and perhaps for Golgi 
network targeting, while the FXXXFXXXF region encodes an endoplasmic reticulum 
export signal that regulates cell surface expression [81]. Motawea and co-workers 
showed that the RRRRR motif in the Į2C-adrenoceptor has a dominant-negative effect 
resulting in an intracellular pool of functional receptors [40]. By mutating all five 
arginines this ER-Golgi retention sequence lost its effect and resulted in increased 
expression at the cell surface. The mechanism is suggested to be that filamin-2, an 
actin-binding protein, binds to the arginine-rich region mentioned and blocks its 
negative influence, resulting in translocation of the receptor to the cell surface. When 
filamin is not bound to the receptor it appears that the RRRRR motif is hindering 
receptor trafficking by negatively dominating over the aforementioned conserved 
export signal. The same research group published in 2000 a paper connecting the Į2C-
adrenoceptor to the Raynaud’s Phenomen [49], and with the identification of the C-
terminal retention sequence there is a possibility in the future of targeting this cascade 
for drug development against this disease. Recently the same group performed in 
silico modeling to further investigate the interaction between filamin-2 and the 
RRRRR motif in the Į2C-adrenoceptor and phylogenetic analysis of the motif [82]. 
The results indicate an interaction between filamin-2 and in particular arginines 454 
and 456, and that these interactions have evolved in warm-blooded animals. With 
regard to an intracellular pool of Į2C-adrenoceptor it remains to be seen whether this 
C-terminal ER-Golgi retention sequence [40] is in addition to, or excludes, the N-
terminal ER retention signal proposed by Angelotti and co-workers [35].  
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4.3.3 The C-terminal half of the Į2C-adrenoceptor determines drug 
selectivity 
Laurila et al. [68] proposed an interaction between TM1 and ECL2 at the Į2A-
adrenoceptor, which would induce a general affinity-lowering effect for bulky drugs. 
Taking advantage of our chimeric Į2A/Į2C-constructs we attempted to verify or 
disprove this hypothesis. The Ki values of seven drugs competing for [3H]-RX821002 
binding were determined at the wild type Į2A- and Į2C-adrenoceptors and at four of 
the chimeric Į2A-/Į2C-adrenoceptors. The chimeras were CtsA, CppA, AppC, and 
AtsCppA (see figure 2 in paper III). The drugs spiroxatrine, clozapine, and 
chlorpromazine were chosen because these molecules are bulky and Į2C/Į2B- over 
Į2A-selective [68], MK912 because it is bulky and Į2C- but not Į2B- over Į2A-selective 
[83], BRL44408 because it is Į2A-selective, and atipamezole and RX820102 because 
they are small and non-selective molecules [67]. Our results show that the Į2C- over 
Į2A-selectivity of spiroxatrine, spiperone, clozapine, MK912 and chlorpromazine, as 
well as the Į2A-over Į2C-selectivity of BRL44408, reside mainly in the C-terminal 
half of the receptors. This half, which is taken from Į2C in AppC, and from Į2A in 
CppA, includes TM5-7, but not most of TMs 1-4. The full binding pocket of 
noradrenaline is known to have direct contact sites for noradrenaline at TM3 and 
TM5 [16]. Thus, all the Į2C-selective ligands, i.e. spiroxatrine, spiperone, clozapine, 
MK912 and chlorpromazine showed selectivity for the Į2C and AppC receptors over 
the Į2A, CtsA, CppA, and AtsCppA receptors. Laurila et al. [68] reported somewhat 
higher affinities for bulky Į2C-selective drugs at CCA (a construct identical to our 
CtsA-construct) as compared to at Į2A. However, in our hands only chlorpromazine, 
among the tested Į2C-selective drugs, showed higher affinity for CtsA than for wild 
type Į2A (2-fold). Our results cast doubt on the hypothesis that there is an Į2A-specific 
conformational interaction between TM1 and ECL2 in the Į2A-adrenoceptor that 
would induce a general affinity-lowering effect for all bulky substances. Instead, our 
results indicate that the C-terminal half of the Į2A- respective Į2C-adrenoceptors, 
independently of other regions, is the main determinant of drug selectivity between 
the Į2A- and Į2C-adrenoceptors. 
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5. CONCLUDING REMARKS 
We have shown in the present project that: 
i) The 5-HT2C receptor has a 32 amino acid long cleavable signal peptide. Cleavage 
of this signal peptide results in a mature receptor that is lacking the amino acid 
affected by the frequent single nucleotide polymorphism denoted Cys23Ser.  
ii) The 5-HT2C receptor’s expression level is decreased when cleavage of the signal 
peptide is obstructed experimentally by mutating an amino acid critical for the 
cleavability. 
iii) If the signal peptide is truncated, the 5-HT2C receptor’s first transmembrane 
segment functions efficiently as a signal anchor. 
iiii) The Į2C-adrenoceptor does not have a 22 amino acid long cleavable signal 
peptide, but it is unresolved whether there is an alternative cleavage site that, if 
functional, would generate a 15 amino acid long signal peptide. 
iii) The Į2C-adrenoceptor’s N-terminal tail does not contribute to the low expression 
level of this receptor, and if truncated the receptor seems unable of efficiently using 
its first transmembrane segment as a signal anchor. The Į2C-adrenoceptor’s N-
terminal is a necessity for efficient expression of binding competent receptors at the 
cell surface. 
iiii) The C-terminal half of the Į2C-adrenoceptor, defined as the region from the end 
of the fourth transmembrane helix to the receptor’s ultimate C-terminus, is 
responsible for both: a) the low expression level of the receptor at the plasma 
membrane, and b) the Į2C- over Į2A-selectivity of “bulky” ligands.   
As far as we can tell, paper I in this project is the first publication highlighting the 
presence of an N-terminal cleavable signal peptide in a monoamine G-protein 
coupled receptor. It is evident from the data presented in this project that the N-
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terminus of monoamine GPCRs has a complex importance for trafficking of the 
receptor from the ribosome to the plasma membrane. This complexity needs to be 
taken into account when planning and interpreting investigations into these receptors.     
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6. FUTURE PERSPECTIVES 
6.1 THE 5-HT2C N-TERMINUS 
6.1.1 Characterization of the binding epitope for the monoclonal 
antibody sc-15081 at the 5-HT2c receptor 
In 2011, the binding epitope for a widely used "N-terminally directed" antibody 
recognizing the 5-HT2C receptor was disclosed, the epitope being amino acids 27-45 
in the N-terminal tail [84]. We wish to prove or disprove whether this antibody, SR-
2C Antibody (N-19): sc-15081 from Santa Cruz Biotechnology, recognizes a 
truncated 5-HT2C receptor, i.e. the receptor where the 32 amino acids long signal 
peptide has been cleaved off. The immunofluorescence study will be performed 
essentially the same way as in our previous study presented in paper I [26], 
examining the receptor constructs A, D, and E from that study. The hypothesis would 
be that the sc-15081 antibody recognizes the truncated receptor. Otherwise, 5-HT2C
receptors identified in publications with this antibody must be uncleaved receptors, 
meaning there might exist two populations of 5-HT2C receptors in the body, namely 
the fraction with cleaved, and the fraction with uncleaved signal peptide.      
6.1.2 Investigating the 5-HT2C N-terminus for alternative signal 
peptide cleavage site 
If the antibody described in the section above does not detect the 32/33-cleaved 5-
HT2C receptor, which lacks the amino acids 27-32 present in the antigenic epitope, 
then additional experiments are warranted to explain why this antibody in fact has 
been shown to label 5-HT2C receptors in several immune-histological studies [84]. 
The latest version of the Signal P prediction software is version 4.1. When analyzing 
the 5-HT2C N-terminus in Signal P 4.1 the software predicts there to be a signal 
peptide with cleavage site after amino acid 22, as opposed to after amino acid 32 with 
version 3.0. This opens up the possibility of multiple cleavage sites, which would be 
interesting to investigate further for this receptor that already is known for 
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undergoing extensive RNA editing. In addition to this, cleavage after 22 amino acids 
would produce a mature protein with the aforementioned SNP Cys23Ser as the first 
amino acid. Although functional studies of the SNP concluded with it having no 
pharmacological relevance for the receptor [25], a mutation in the +1 position of a 
signal peptide could be interesting to investigate. Exchanging cysteine for serine at 
position 23 does not affect the prediction results in either of the Signal P versions 
noteworthy. The hypothesis would be that the 5-HT2C receptor is functionally 
expressed with different structures, meaning that the N-terminus has more than one 
cleavage site.  
6.2 THE ALPHA2C-ADRENOCEPTOR N-TERMINUS 
6.2.1 Investigation of alternative signal peptide cleavage site 
predicted for the Į2C-adrenoceptor 
The study is motivated by the results obtained in paper II and developments in the 
signal peptide prediction software SignalP. In paper II we show that the predicted 22 
amino acid long signal peptide is not a functional signal peptide, and that the 
endogenous N-terminus tail is essential for expression of binding competent 
receptors. When analyzing the Į2C N-terminus in SignalP 4.1 with the setting 
optimized for sensitivity, the software predicts there to be a signal peptide with 
cleavage site after the 15th amino acid. Only one new construct has to be made and 
tested, in order to verify or disprove an alternative signal peptide cleavage site for the 
Į2C-adrenoceptor. We will produce a new Į2C-adrenoceptor construct, with the 
FLAG-epitope inserted after 15 amino acids in the N-terminal of the receptor. The 
construct will be tested the same way as in our previous study in paper II [34]. In 
addition, we will make a non-cleavable Į2C-constructs, where alanine (A) at position 
15 in the N-terminal tail “MASPALAAALAVAAAAGPNASG-AGER…” will be 
exchanged for asparagine (N). The expression levels for the constructs will be tested 
by radioligand binding. The hypothesis would be that the Į2C-adrenoceptor N-
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terminus indeed has a cleavable signal peptide, although with a different cleavage site 
than we investigated in paper II.  
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8. APPENDIX 
An overview of the 20 amino acids with abbreviations and structure. 
The figure is a modified version of a figure made by Dan Cojocari (Department of 
Medical Biophysics, University of Toronto, Canada) published in the Wikimedia 
Commons database. 
